Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus PBZ SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus PBZ SR.
HISTAFED vs PBZ-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Antihistamine; H1-receptor antagonist that competes with histamine for binding at H1 receptor sites, thereby preventing histamine-mediated allergic responses.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
100-200 mg orally every 12 hours; maximum 400 mg/day.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Terminal elimination half-life is approximately 4-6 hours in adults with normal renal function; clinically relevant dosing every 4-6 hours is recommended.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Primarily renal excretion (80-90% as unchanged drug) via glomerular filtration and tubular secretion. Biliary/fecal excretion accounts for approximately 5-10%.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine